Brief Summary

The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.

Approved for marketing
Hemoglobinuria, Paroxysmal

Drug: eculizumab
600mg IV every week and 900mg IV every 2 weeks

Eligibility Criteria

Inclusion Criteria: - PNH; - At least 18 years old - Avoid conception; and - Willing and able to give written informed consent

Exclusion Criteria: - Active bacterial infection - Participation in any other drug trial - Pregnant breast feeding, or intending to conceive - Not vaccinated against N meningitidis

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
United States
Locations

Anthony Botti
Livingston, New Jersey,

Alexion Pharmaceuticals
NCT Number
MeSH Terms
Hemoglobinuria
Hemoglobinuria, Paroxysmal
Intervention Name
eculizumab